SCHEMBL7704833

SCHEMBL7704833

CC1Oc2ccc(C(NC(=O)OC(C)(C)C)C3Cc4ccccc4C3)cc2N=C1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
RCE1 Q9Y256 1/20 0.37
PLA2G1B P04054 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
XBP1 P17861 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
AAK1 Q2M2I8 3/20 0.35
EPHX2 P34913 1/20 0.31
S1PR3 Q99500 1/20 0.31
CTSS P25774 1/20 0.31
CTSK P43235 1/20 0.31
EDNRA P25101 1/20 0.31
RORC P51449 1/20 0.31
ROCK2 O75116 2/20 0.31
BACE1 P56817 1/20 0.31
CXCR3 P49682 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7705017 0.86 ALDH1A1 (0.34) KDM4EALDH1A1RCE1PLA2G1BMAPT
SCHEMBL7704912 0.80 ALDH1A1 (0.45) ALDH1A1MAPTHPGDXBP1HTT
SCHEMBL7089999 0.78 KDM4E (0.37) KDM4EALDH1A1RCE1PLA2G1BMAPT
SCHEMBL7704992 0.77 ALDH1A1 (0.35) KDM4EALDH1A1RCE1PLA2G1BMAPT
SCHEMBL7710869 0.77 CTSS (0.42) KDM4EALDH1A1RCE1PLA2G1BMAPT
SCHEMBL7704969 0.77 ALDH1A1 (0.36) ALDH1A1MAPTHPGDXBP1HTT
SCHEMBL7711115 0.77 AAK1 (0.40) KDM4EALDH1A1RCE1PLA2G1BMAPT
SCHEMBL7711369 0.76 ALDH1A1 (0.37) KDM4EALDH1A1RCE1MAPTHPGD
SCHEMBL7708193 0.76 ALDH1A1 (0.38) KDM4EALDH1A1RCE1PLA2G1BMAPT
SCHEMBL7708356 0.75 CTSS (0.41) ALDH1A1MAPTHPGDXBP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed